Document is current

Article History

Accepted: 14 October 2024

First Online: 24 November 2024

Declarations

:

: The authors have received no funding for this work.

: F.D.A. has received speaker honoraria from Neurology Academy, Janssen, Merck, Novartis, Sanofi and served in an advisory board for Novartis, Sanofi and Coloplast. She has received congress fees from Janssen, Novartis, Roche and Merck. She is a regional coordinator for the Oratorio Hand Trial (Hoffmann-La Roche) and a Principal Investigator of commercial and academic trials included CHARIOT-MS, ALITHIOS (Novartis), O’HAND (Roche). She has received a research grant from the Multiple Sclerosis Society of Great Britain and Northern Ireland and funding from National Brain Appeal – Small Acorns fund. R.N. has received a MAGNIMS-ECTRIMS fellowship. S.W. has received congress fees from Merck and Roche and speaker honoraria from Neurology Academy.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable given the nature of this paper (narrative review).

: Not applicable.

: FDA: concept and design of the work, project organisation, writing of the first draft, review and critique. RN: writing of the first draft, review and critique. SW: writing of the first draft, review and critique. All authors have read and approved the final version and agree to be accountable for the work.